The pathophysiologic changes occurring in cardiovascular disease can affect the kinetics of drugs in several different ways. The present review examines these modifications and the underlying mechanisms. The kinetics of specific agents, such as antiarrhythmic, antihypertensive, cardiotonic, and other drugs are considered, and the clinical implications are outlined. The clinician should be aware of these modifications, because they require an adjustment of the dosage regimen. A rational basis for a correct therapeutic choice can be provided by adequate knowledge of these modifications.
Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter
Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function
Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarction
Influence of congestive heart failure on blood vessels of lidocaine and its active monodeethylated metabolite
Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension
The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction
Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure
Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure
Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension
Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents
Plasma nitrendipine concentrations in elderly hypertensive patients after single and multiple dosing
Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure
Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects
N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives
Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration
Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood
Plasma free captopril concentrations during short and long term treatment with oral captopril for heart failure
Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure
Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment
Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure
Relation between serum quinidine levels and renal function. Studies in normal subjects and patients with congestive failure and renal insufficiency
Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients
Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide
Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe chronic congestive heart failure
Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure
Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil
Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction
Antiarrhythmic efficacy, pharmacokinetics and clinical safety of tocainide in convalescent myocardial infarction patients
Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure
Factors influencing procainamide total body clearance in the immediate postmyocardial infarction period
Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction
Quinidine concentration in blood and excretion in urine following parenteral administration as related to congestive heart failure
The biochemistry of drug metabolism--an introduction: part 7. Intra-individual factors affecting drug metabolism
Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly
Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.
Identification of biomarkers for the prognosis of pancreatic ductal adenocarcinoma with miRNA microarray data
Antiarrhythmic Agents: Mechanisms of Action
Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.
Antihypertensive Agents: Mechanisms of Action
Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.
Anti-Arrhythmic Drug Therapies
Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.
Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.